Not exact matches
Currently, seasonal flu vaccines are designed to induce high levels of protective antibodies
against hemagglutinin (HA), a protein found on the surface of the
influenza virus that enables the
virus to enter a human
cell and initiate infection.
Scientists from Tomsk Polytechnic University together with their colleagues from St. Petersburg and London have elaborated a new approach to deliver anti-viral RNAi to target
cells against H1N1
influenza virus infection.
«Given these results in
cells and mice, it may be worthwhile to consider that patients receiving, or who may receive, Amphotericin B - based therapies be appropriately vaccinated
against influenza virus.
This protein can protect cultured human
cells from avian
influenza viruses but is ineffective
against strains that have acquired the ability to infect humans.
Broadly cross-reactive antibodies dominate the human B
cell response
against 2009 pandemic H1N1
influenza virus infection
The study relates to a particular type of vaccine (killed)
against a particular
virus,
influenza, though the findings might hold true for other killed vaccines and for those vaccines consisting only of proteins produced by GM in bacteria, yeast or insect
cells,
against diseases such as hepatitis B (HBV) and human papilloma
virus (HPV, the causative agent of cervical cancer).